Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia
Condition: Plasma Cell Leukemia; Plasma Cell Myeloma; Plasmacytoma
MeSH terms: Leukemia; Multiple Myeloma; Neoplasms, Plasma Cell; Plasmacytoma; Leukemia, Plasma Cell
Intervention: Dexamethasone; Ixazomib Citrate; Laboratory Biomarker Analysis; Pomalidomide
Intervention description: Given PO; Given PO; Correlative studies; Given PO
Intervention MeSH terms: Dexamethasone; Dexamethasone acetate; Pomalidomide; Ixazomib; Ichthammol; BB 1101; Glycine
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 17.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      This phase II trial studies how well pomalidomide, ixazomib citrate, and dexamethasone work
      in treating patients with previously treated multiple myeloma or plasma cell leukemia.
      Biological therapies, such as pomalidomide and dexamethasone, use substances made from living
      organisms that may stimulate or suppress the immune system in different ways and stop cancer
      cells from growing. Ixazomib citrate may stop the growth of cancer cells by blocking some of
      the enzymes needed for cell growth. Giving pomalidomide, ixazomib citrate, and dexamethasone
      together may be more effective in treating multiple myeloma.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Previously treated myeloma, currently with extramedullary disease (defined as
             plasmacytoma outside bone marrow that is not contiguous with a bone lesion) with at
             least one lesion that has a single diameter of >= 2 cm or plasma cell leukemia
             (defined as circulating plasma cells exceeding 5% of peripheral blood leukocytes or
             0.5 X 10^9/L or 200 cells/150000 events by flow cytometry)

          -  Calculated creatinine clearance (using Cockcroft-Gault equation) >= 30 mL/min

          -  Absolute neutrophil count (ANC) >= 1000/mm^3

          -  Platelet count >= 50,000/mm^3

          -  Hemoglobin >= 8.0 g/dL

          -  Patients with measurable disease defined as at least one of the following:

               -  For patients with extramedullary disease (EMD) measurable disease by computed
                  tomography (CT) or magnetic resonance imaging (MRI) or the CT portion of the
                  positron emission tomography (PET)/CT: must have at least one lesion that has a
                  single diameter of >= 2 cm; skin lesions can be used if the area is >= 2 cm in at
                  least one diameter and measured with a ruler

               -  Plasma cell count >= 0.5 X 10^9/L or 5 percent of the peripheral blood white
                  cells

               -  Plasma cell count if determined by flow cytometry, >= 200/150,000 events

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2

          -  Provide informed written consent

          -  Negative pregnancy test done =< 7 days prior to registration, for women of
             childbearing potential only

          -  All study participants must be registered into the mandatory pomalidomide (POMALYST)
             Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to
             comply with the requirements of the POMALYST REMS program

          -  Willing to return to enrolling institution for follow-up (during the active monitoring
             phase of the study)

          -  Willing to provide bone marrow and blood samples for correlative research purposes

        Exclusion Criteria:

          -  Other malignancy requiring active therapy

               -  EXCEPTIONS: Non-melanoma skin cancer, ductal breast carcinoma in situ (DCIS) or
                  carcinoma-in-situ of the cervix

               -  NOTE: If there is a history or prior malignancy, they must not be receiving other
                  specific treatment for their cancer

          -  Females of childbearing potential (FCBP)* must have a negative serum pregnancy test
             with a sensitivity of at least 50 mIU/mL within 10-14 days prior to and again within
             24 hours prior to prescribing pomalidomide for cycle 1 (prescriptions must be filled
             within 7 days as required by RevAssist [lenalidomide REMS program]), and must either
             commit to continued abstinence from heterosexual intercourse or begin TWO acceptable
             methods of birth control, one highly effective method and one additional effective
             method; AT THE SAME TIME, at least 28 days before she starts taking pomalidomide FCBP
             must also agree to ongoing pregnancy testing; men must agree to use a latex condom
             during sexual contact with a FCBP even if they have had a successful vasectomy;
             patient must follow pregnancy testing requirements as outlined in the POMALYST REMS
             program

               -  A female of childbearing potential is a sexually mature woman who: 1) has not
                  undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally
                  postmenopausal for at least 24 consecutive months (i.e., has had menses at any
                  time in the preceding 24 consecutive months)

          -  Nursing women

          -  Men or women of childbearing potential who are unwilling to employ adequate
             contraception

          -  Other co-morbidity which would interfere with patient's ability to participate in
             trial, e.g. uncontrolled infection, uncompensated heart or lung disease

          -  Other concurrent chemotherapy, radiotherapy, or any ancillary therapy considered
             investigational

               -  NOTE: Bisphosphonates are considered to be supportive care rather than therapy,
                  and are thus allowed while on protocol treatment

          -  Patient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical
             examination during the screening period

          -  Major surgery =< 14 days before study registration

          -  Systemic treatment with strong CYP3A4 inducers (e.g. rifampin, rifapentine, rifabutin,
             carbamazepine, phenytoin, phenobarbital, gingko biloba, St. John's wort) within 7 days
             before registration

          -  Evidence of current uncontrolled cardiovascular conditions, including cardiac
             arrhythmias, congestive heart failure, angina, or myocardial infarction within the
             past 6 months; Note: prior to study entry, any electrocardiogram (ECG) abnormality at
             screening must be documented by the investigator as not medically relevant

          -  Corrected QT Interval (QTc) > 470 milliseconds (msec) on a 12-lead ECG obtained during
             the screening period

               -  Note: If a machine reading is above this value, the ECG should be reviewed by a
                  qualified reader and confirmed on a subsequent ECG

          -  Known human immunodeficiency virus (HIV) positive

          -  Known hepatitis B surface antigen-positive status, or known or suspected active
             hepatitis C infection

          -  Any serious medical or psychiatric illness that could, in the investigator's opinion,
             potentially interfere with the completion of treatment according to this protocol

          -  Known allergy to any of the study medications, their analogues or excipients in the
             various formulations

          -  Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral
             absorption or tolerance of ixazomib including difficulty swallowing

          -  Diarrhea > grade 1, based on the National Cancer Institute Common Terminology Criteria
             for Adverse Events (NCI CTCAE) grading, in the absence of antidiarrheals